aTyr Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Revenue	0.35	10.39	0	10.46	0.42	Upgrade
Revenue Growth (YoY)	-96.60%	-	-	2377.49%	-	Upgrade
Gross Profit	0.35	10.39	0	10.46	0.42	Upgrade
Selling, General & Admin	12.98	13.98	10.75	9.08	9.35	Upgrade
Research & Development	42.29	42.81	23.26	17.29	14.05	Upgrade
Operating Expenses	55.27	56.79	34.02	26.37	23.4	Upgrade
Operating Income	-54.92	-46.4	-34.02	-15.91	-22.98	Upgrade
Other Expense / Income	-4.53	-1.07	-0.25	0.31	0.63	Upgrade
Pretax Income	-50.39	-45.34	-33.77	-16.22	-23.6	Upgrade
Net Income	-50.39	-45.34	-33.77	-16.22	-23.6	Upgrade
Shares Outstanding (Basic)	54	28	19	9	3	Upgrade
Shares Outstanding (Diluted)	54	28	19	9	3	Upgrade
Shares Change	88.63%	48.94%	108.30%	172.98%	56.66%	Upgrade
EPS (Basic)	-0.94	-1.60	-1.77	-1.77	-7.03	Upgrade
EPS (Diluted)	-0.94	-1.60	-1.77	-1.77	-7.03	Upgrade
Free Cash Flow	-37.42	-43.35	-33.22	-15.49	-20.04	Upgrade
Free Cash Flow Per Share	-0.70	-1.52	-1.74	-1.69	-5.97	Upgrade
Gross Margin	100.00%	100.00%	-	100.00%	100.00%	Upgrade
Operating Margin	-15557.79%	-446.79%	-	-152.19%	-5445.02%	Upgrade
Profit Margin	-14274.50%	-436.53%	-	-155.18%	-5593.13%	Upgrade
Free Cash Flow Margin	-10600.85%	-417.37%	-	-148.11%	-4749.05%	Upgrade
EBITDA	-47.65	-43.64	-32.46	-14.96	-22.24	Upgrade
EBITDA Margin	-13498.02%	-420.21%	-	-143.07%	-5269.43%	Upgrade
Depreciation & Amortization	2.74	1.7	1.3	1.27	1.37	Upgrade
EBIT	-50.39	-45.34	-33.77	-16.22	-23.6	Upgrade
EBIT Margin	-14274.50%	-436.53%	-	-155.18%	-5593.13%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).